Use of probiotics in the treatment of inflammatory bowel disease

Journal of Clinical Gastroenterology

Volumn 36, Issue 2, 2003, Pages 111-119

  Hart, Ailsa L ^a,b   Stagg, Andrew J ^b   Kamm, Michael A ^a  

^a ST MARK S HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Clinical trials; Inflammatory bowel disease; Probiotics

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; MESALAZINE; PROBIOTIC AGENT; STEROID;

ANIMAL MODEL; BACTERIAL FLORA; COLITIS; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; HUMAN; ILEITIS; IMMUNE RESPONSE; INTESTINE FUNCTION; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; ULCERATIVE COLITIS;

ANIMALS; BACTERIA; CONTROLLED CLINICAL TRIALS; EVIDENCE-BASED MEDICINE; HUMANS; INFLAMMATORY BOWEL DISEASES; PROBIOTICS; TREATMENT OUTCOME; YEASTS;

EID: 12244283697     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200302000-00005     Document Type: Review

References (119)

1. Hart AL, Stagg AJ, Frame M, et al. Review article: the role of the gut flora in health and disease, and its modification as a therapy. Aliment Pharmacol Ther 2002;16:1-11.
2. Hart AL, Stagg AJ, Graffner H, et al., eds. Gut ecology. London: Martin Dunitz Ltd, 2002.
3. Fuller R. Probiotics in man and animals. J Appl Bacteriol 1989;66:365-78.
4. Salminen S, Isolauri E, Salminen E. Clinical uses of probiotics for stabilizing the gut mucosal barrier: successful strains and future challenges. Antonie Van Leeuwenhoek 1996;70:347-58.
5. Hamilton-Miller JM, Shah S. Deficiencies in microbiologic quality and labeling of probiotic supplements. Int J Food Microbiol 2002;72:175-6.
6. Katz JA, Pirovano F, Matteuzzi D, et al. Commercially available probiotic preparations: are you getting what you pay for? [abstract]. Gastroenterology 2002;122:T1342.
7. Weese JS. Microbiologic evaluation of commercial probiotics. J Am Vet Med Assoc 2002;220:794-7.
8. Yeung PS, Sanders ME, Kitts CL, et al. Species-specific identification of commercial probiotic strains. J Dairy Sci 2002;85:1039-51.
9. Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am 1995;24:475-507.
10. Wirtz S, Neurath MF. Animal models of intestinal inflammation: new insights into the molecular pathogenesis and immunotherapy of inflammatory bowel disease. Int J Colorectal Dis 2000;15:144-60.
11. Dianda L, Hanby AM, Wright NA, et al. T cell receptor-alpha beta-deficient mice fail to develop colitis in the absence of a microbial environment. Am J Pathol 1997;150:91-7.
12. Sartor RB. Microbial factors in the pathogenesis of Crohn's disease, ulcerative colitis and experimental intestinal inflammation. In: Kirsner JB, ed. Inflammatory Bowel Disease, 5th ed. WB Saunders, 1999:153-78.
13. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immunol 1998;66:5224-31.
14. Taurog JD, Richardson JA, Croft JT, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994;180:2359-64.
15. Janowitz HD, Croen EC, Sachar DB. The role of the fecal stream in Crohn's disease: an historical and analytic review. Inflamm Bowel Dis 1998;4:29-39.
16. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990;99:956-63.
17. Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991;338:771-4.
18. Tytgat GN, Mulder CJ, Brummelkamp WH. Endoscopic lesions in Crohn's disease early after ileocecal resection. Endoscopy 1988;20:260-2.
19. D'Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998;114:262-7.
20. Harper PH, Lee EC, Kettlewell MG, et al. Role of the faecal stream in the maintenance of Crohn's colitis. Gut 1985;26:279-84.
21. Rath HC, Wilson KH, Sartor RB. Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus or Escherichia coli. Infect Immunol 1999;67:2969-74.
22. Balish E, Warner T. Enterococcus faecalis induces inflammatory bowel disease in interleukin-10 knockout mice. Am J Pathol 2002;160:2253-7.
23. Boudeau J, Glasser AL, Masseret E, et al. Invasive ability of an Escherichia coli strain isolated from the ileal mucosa of a patient with Crohn's disease. Infect Immunol 1999;67:4499-509.
24. Boudeau J, Barnich N, Darfeuille-Michaud A. Type I pili-mediated adherence of Escherichia coli strain LF82 isolated from Crohn's disease is involved in bacterial invasion of intestinal epithelial cells. Mol Microbiol 2001;39:1272-84.
25. Darfeuille-Michaud A, Neut C, Barnich N, et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 1998;115:1405-13.
26. Glasser AL, Boudeau J, Barnich N, et al. Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death. Infect Immunol 2001;69:5529-37.
27. Sutton CL, Kim J, Yamane A, et al. Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology 2000;119:23-31.
28. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002;122:44-54.
29. Fabia R, Ar'Rajab A, Johansson ML, et al. Impairment of bacterial flora in human ulcerative colitis and experimental colitis in the rat. Digestion 1993;54:248-55.
30. Favier C, Neut C, Mizon C, et al. Fecal beta-D-galactosidase production and Bifidobacteria are decreased in Crohn's disease. Dig Dis Sci 1997;42:817-22.
31. Ruseler-van Embden JG, Schouten WR, van Lieshout LM. Pouchitis: result of microbial imbalance? Gut 1994;35:658-64.
32. Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001;121:580-91.
33. Madsen KL, Doyle JS, Jewell LD, et al. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999;116:1107-14.
34. Madsen KL, Doyle JS, Tavernini MM, et al. Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice. Gastroenterology 2000;118:1094-105.
35. Duchmann R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995;102:448-55.
36. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
37. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
38. Mao Y, Nobaek S, Kasravi B, et al. The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats. Gastroenterology 1996;111:334-44.
39. Fabia R, Ar'Rajab A, Johansson ML, et al. The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic acid-induced colitis in the rat. Scand J Gastroenterol 1993;28:155-62.
40. Holma R, Salmenpera P, Lohi J, et al. Effects of Lactobacillus rhamnosus GG and Lactobacillus reuteri R2LC on acetic acid-induced colitis in rats. Scand J Gastroenterol 2001;36:630-5.
41. Schultz M, Veltkamp C, Dieleman LA, et al. Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. Inflamm Bowel Dis 2002;8:71-80.
42. O'Mahony L, Feeney M, O'Halloran S, et al. Probiotic impact on microbial flora, inflammation and tumor development in IL-10 knockout mice. Aliment Pharmacol Ther 2001;15:1219-25.
43. Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000;289:1352-5.
44. Sandborn WJ. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology 1994;107:1856-60.
45. Keighley MR. Review article: the management of pouchitis. Aliment Pharmacol Ther 1996;10:449-57.
46. Nicholls RJ, Banerjee AK. Pouchitis: risk factors, etiology, and treatment. World J Surg 1998;22:347-51.
47. Gionchetti P, Rizzello F, Venturi A, et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 1999;13:713-8.
48. Gionchetti P, Amadini C, Rizzello F, et al. Treatment of mild to moderate ulcerative colitis and pouchitis. Aliment Pharmacol Ther 2002;16(Suppl 4):13-9.
49. Madden MV, McIntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 1994;39:1193-6.
50. Shen B, Achkar JP, Lashner BA, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001;7:301-5.
51. Mimura T, Rizzello F, Helwig U, et al. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther 2002;16:909-17.
52. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:305-9.
53. Mimura T, Rizzello F, Schreiber S, et al. Once daily high dose probiotic therapy maintains remission and improves quality of life in patients with recurrent or refractory pouchitis: a randomised, placebo-controlled, double-blind trial [abstract]. Gastroenterology 2002;122:667.
54. Gionchetti P, Rizzello F, Venturi A, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind placebo-controlled trial [abstract]. Gastroenterology 2000;118:1214.
55. Friedman G, George J. Treatment of refractory "pouchitis" with prebiotic and probiotic therapy [abstract]. Gastroenterology 2000;118:4167.
56. Gibson GR. Dietary modulation of the human gut microflora using the prebiotics oligofructose and inulin. J Nutr 1999;129:1438S-41S.
57. Nissle A. Übersicht über die Bedeutung bakteriologischer Stuhluntersuchungen bei nichtinfektiösen Darmerkrankungen. Arch Hyg Bakt 1930;103:124-31.
58. Burke DA, Axon AT. Ulcerative colitis and Escherichia coli with adhesive properties. J Clin Pathol 1987;40:782-6.
59. Giaffer MH, Holdsworth CD, Duerden BI. Virulence properties of Escherichia coli strains isolated from patients with inflammatory bowel disease. Gut 1992;33:646-50.
60. Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853-8.
61. Kruis W, Fric P, Stolte M, et al. Maintenance of remission in ulcerative colitis is equally effective with Escherichia coli 1917 and with standard mesalamine [abstract]. Gastroenterology 2001;120:680.
62. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354:635-9.
63. Dissanayake AS, Truelove SC. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin). Gut 1973;14:923-6.
64. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999;13:1103-8.
65. McFarland LV, Surawicz CM, Greenberg RN, et al. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995;90:439-48.
66. Surawicz CM, Elmer GW, Speelman P, et al. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 1989;96:981-8.
67. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994;271:1913-8.
68. Plein K, Hotz J. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea-a pilot study. Z Gastroenterol 1993;31:129-34.
69. Guslandi M, Mezzi G, Sorghi M, et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000;45:1462-4.
70. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997;25:653-8.
71. Campieri M, Rizzello F, Venturi A, et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of postoperative recurrence of Crohn's disease: a randomised controlled study versus mesalazine [abstract]. Gastroenterology 2000;118:4179.
72. McCarthy J, O'Mahony L, Dunne C, et al. An open trial of a novel probiotic as an alternative to steroids in mild/moderately active Crohn's disease [abstract]. Gut 2001;49(Suppl III):2447.
73. Malin M, Suomalainen H, Saxelin M, et al. Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab 1996;40:137-45.
74. Gupta P, Andrew H, Kirschner BS, et al. Is lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr 2000;31:453-7.
75. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999;13:1103-8.
76. Mack DR, Michail S, Wei S, et al. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol 1999;276:G941-50.
77. Flynn S, van Sinderen D, Thornton GM, et al. Characterization of the genetic locus responsible for the production of ABP-118, a novel bacteriocin produced by the probiotic bacterium Lactobacillus salivarius subsp. salivarius UCC118. Microbiology 2002;148:973-84.
78. Schmitz H, Barmeyer C, Fromm M, et al. Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology 1999;116:301-9.
79. Hilsden RJ, Meddings JB, Sutherland LR. Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease. Gastroenterology 1996;110:1395-403.
80. Hollander D, Vadheim CM, Brettholz E, et al. Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann Intern Med 1986;105:883-5.
81. May GR, Sutherland LR, Meddings JB. Is small intestinal permeability really increased in relatives of patients with Crohn's disease? Gastroenterology 1993;104:1627-32.
82. Peeters M, Geypens B, Claus D, et al. Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterology 1997;113:802-7.
83. Wyatt J, Vogelsang H, Hubl W, et al. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993;341:1437-9.
84. Sakaguchi T, Kohler H, Gu X, et al. Shigella flexneri regulates tight junction-associated proteins in human intestinal epithelial cells. Cell Microbiol 2002;4:367-81.
85. Kennedy RJ, Hoper M, Deodhar K, et al. Probiotic therapy fails to improve gut permeability in a hapten model of colitis. Scand J Gastroenterol 2000;35:1266-71.
86. Garcia-Lafuente A, Antolin M, Guarner F, et al. Modulation of colonic barrier function by the composition of the commensal flora in the rat. Gut 2001;48:503-7.
87. Kaila M, Isolauri E, Soppi E, et al. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatr Res 1992;32:141-4.
88. Fukushima Y, Kawata Y, Hara H, et al. Effect of a probiotic formula on intestinal immunoglobulin A production in healthy children. Int J Food Microbiol 1998;42:39-44.
89. Tejada-Simon MV, Lee JH, Ustunol Z, et al. Ingestion of yogurt containing Lactobacillus acidophilus and Bifidobacterium to potentiate immunoglobulin A responses to cholera toxin in mice. J Dairy Sci 1999;82:649-60.
90. Perdigon G, de Macias ME, Alvarez S, et al. Systemic augmentation of the immune response in mice by feeding fermented milks with Lactobacillus casei and Lactobacillus acidophilus. Immunology 1988;63:17-23.
91. Perdigon G, Vintini E, Alvarez S, et al. Study of the possible mechanisms involved in the mucosal immune system activation by lactic acid bacteria. J Dairy Sci 1999;82:1108-14.
92. Haller D, Blum S, Bode C, et al. Activation of human peripheral blood mononuclear cells by nonpathogenic bacteria in vitro: evidence of NK cells as primary targets. Infect Immunol 2000;68:752-9.
93. Haller D, Bode C, Hammes WP, et al. Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithetial cell/leukocyte co-cultures. Gut 2000;47:79-87.
94. Helgeland L, Vaage JT, Rolstad B, et al. Microbial colonization influences composition and T-cell receptor V beta repertoire of intraepithelial lymphocytes in rat intestine. Immunology 1996;89:494-501.
95. Herias MV, Hessle C, Telemo E, et al. Immunomodulatory effects of Lactobacillus plantarum colonizing the intestine of gnotobiotic rats. Clin Exp Immunol 1999;116:283-90.
96. Eckmann L, Jung HC, Schurer-Maly C, et al. Differential cytokine expression by human intestinal epithelial cell lines: regulated expression of interleukin 8. Gastroenterology 1993;105:1689-97.
97. Neish AS, Gewirtz AT, Zeng H, et al. Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science 2000;289:1560-3.
98. O'Mahony L, Feeney M, MacSharray J, et al. Probiotics, mononuclear cells and epithelial cells: an anti-inflammatory network [abstract]. Gastroenterology 2000;118:680.
99. Schultz M, Linde H, Staudner H, et al. Oral administration of Lactobacillus GG induces an anti-inflammatory Th2 mediated systemic response towards intestinal organisms [abstracts]. Gastroenterology 2000;118:4180.
100. Ulisse S, Gionchetti P, D'Alo S, et al. Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol 2001;96:2691-9.
101. Kelsall BL, Strober W. Peyer's patch dendritic cells and the induction of mucosal immune responses. Res Immunol 1997;148:490-8.
102. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
103. Kalinski P, Hilkens CM, Wierenga EA, et al. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 1999;20:561-7.
104. Kronin V, Hochrein H, Shortman K, et al. Regulation of T cell cytokine production by dendritic cells. Immunol Cell Biol 2000;78:214-23.
105. Huang Q, Liu D, Majewski P, et al. The plasticity of dendritic cell responses to pathogens and their components. Science 2001;294:870-5.
106. Rigby RJ, Hart AL, Kamm MA, et al. Differential production of 1L-12 and 1L-10 by colonic dendritic cells in response to bacterial stimuli [abstract]. Gastroenterology 2002;122:633.
107. O'Mahony L, Zong Y, Sharma S, et al. Probiotic bacteria and pathogenic hacteria elicit differential cytokine responses from dendritic cells [abstract]. Gastroenterology 2001;120:1625.
108. Rachmilewitz D, Karmeli F, Takabayashi K, et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology 2002;122:1428-41.
109. Rachmilewitz D, Karmeli F, Takabayashi K, et al. Amelioration of experimental colitis by probiotics is due to the immunostimulatory effects of its DNA [abstract]. Gastroenterology 2002;122:T1004.
110. Rautio M, Jousimies-Somer H, Kauma H, et al. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 1999;28:1159-60.
111. Piarroux R, Millon L, Bardonnet K, et al. Are live saccharomyces yeasts harmful to patients? Lancet 1999;353:1851-2.
112. Pletincx M, Legein J, Vandenplas Y. Fungemia with Saccharomyces boulardii in a 1-year-old girl with protracted diarrhea. J Pediatr Gastroenterol Nutr 1995;21:113-5.
113. Horwitch CA, Furseth HA, Larson AM, et al. Lactobacillemia in three patients with AIDS. Clin Infect Dis 1995;21:1460-2.
114. Saxelin M, Chuang NH, Chassy B, et al. Lactobacilli and bacteremia in southern Finland, 1989-1992. Clin Infect Dis 1996;22:564-6.
115. Chomarat M, Espinouse D. Lactobacillus rhamnosus septicemia in patients with prolonged aplasia receiving ceftazidime-vancomycin. Eur J Clin Microbiol Infect Dis 1991;10:44.
116. Patel R, Cockerill FR, Porayko MK, et al. Lactobacillemia in liver transplant patients. Clin Infect Dis 1994;18:207-12.
117. Farina C, Arosio M, Mangia M, et al. Lactobacillus casei subsp, rhamnosus sepsis in a patient with ulcerative colitis. J Clin Gastroenterol 2001;33:251-2.
118. Palmeros B, Wild J, Szybalski W, et al. A family of removable cassettes designed to obtain antibiotic-resistance-free genomic modifications of Escherichia coli and other bacteria. Gene 2000;247:255-64.
119. Recorbet G, Robert C, Givaudan A, et al. Conditional suicide system of Escherichia coli released into soil that uses the Bacillus subtilis sacB gene. Appl Environ Microbiol 1993;59:1361-6.